{"DataElement":{"publicId":"12566449","version":"1","preferredName":"Diffuse Large B-Cell Lymphoma Origin Cell Name Code","preferredDefinition":"A coded response to indicate the origin of diffuse large B-cell lymphomas.","longName":"12564979v1.00:12564956v1.00","context":"SWOG","contextVersion":"1","DataElementConcept":{"publicId":"12564979","version":"1","preferredName":"Diffuse Large B-Cell Lymphoma Origin Cell Name","preferredDefinition":"A non-Hodgkin lymphoma characterized by a diffuse proliferation of predominantly large neoplastic B lymphocytes.  It is the most frequently seen type of non-Hodgkin lymphoma, representing 30%-40% of the cases.  Morphologic variants include centroblastic lymphoma, immunoblastic lymphoma, and anaplastic lymphoma.  Subtypes/entities include T-cell/histiocyte rich large B-cell lymphoma, primary diffuse large B-cell lymphoma of the central nervous system, plasmablastic lymphoma, primary cutaneous diffuse large B-cell lymphoma, leg type, and ALK-positive large B-cell lymphoma.:The name of the cell from which the biological specimen was derived.","longName":"2478319v1.00:12564978v1.00","context":"SWOG","contextVersion":"1","ObjectClass":{"publicId":"2478319","version":"1","preferredName":"Diffuse Large B-Cell Lymphoma","preferredDefinition":"This non-Hodgkin's lymphoma is characterized by a diffuse proliferation of predominantly large neoplastic B lymphocytes.  It is the most frequently seen type of non-Hodgkin's lymphoma, representing 30%-40% of the cases.  Morphologic variants include centroblastic lymphoma, immunoblastic lymphoma, T-cell/histiocyte rich lymphoma, anaplastic lymphoma, plasmablastic lymphoma, and diffuse large B-cell lymphoma with expression of full-length ALK. (WHO, 2001) -- 2003","longName":"C8851","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Diffuse Large B-Cell Lymphoma","conceptCode":"C8851","definition":"A non-Hodgkin lymphoma characterized by a diffuse proliferation of predominantly large neoplastic B lymphocytes.  It is the most frequently seen type of non-Hodgkin lymphoma, representing 30%-40% of the cases.  Morphologic variants include centroblastic lymphoma, immunoblastic lymphoma, and anaplastic lymphoma.  Subtypes/entities include T-cell/histiocyte rich large B-cell lymphoma, primary diffuse large B-cell lymphoma of the central nervous system, plasmablastic lymphoma, primary cutaneous diffuse large B-cell lymphoma, leg type, and ALK-positive large B-cell lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"11E01CB8-267E-253F-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-04-20","endDate":null,"createdBy":"SHIDED","dateCreated":"2006-04-20","modifiedBy":"ONEDATA","dateModified":"2006-04-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"12564978","version":"1","preferredName":"Origin Cell Name","preferredDefinition":"The name of the cell from which the biological specimen was derived.","longName":"C164570","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Origin Cell Name","conceptCode":"C164570","definition":"The name of the cell from which the biological specimen was derived.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F4B02337-5F71-7CFA-E053-731AD00A981E","latestVersionIndicator":"Yes","beginDate":"2023-02-14","endDate":null,"createdBy":"FINCHAMB","dateCreated":"2023-02-14","modifiedBy":"FINCHAMB","dateModified":"2023-02-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"SWOG CRF:Southwest Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F4B02337-5F72-7CFA-E053-731AD00A981E","latestVersionIndicator":"Yes","beginDate":"2023-02-14","endDate":null,"createdBy":"FINCHAMB","dateCreated":"2023-02-14","modifiedBy":"FINCHAMB","dateModified":"2023-11-01","changeDescription":"11/7/2019: CM Released as part of draft content review","administrativeNotes":"2/14/23 Created for SWOG. BF;","unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"12564956","version":"1","preferredName":"Origin Cell Name Code","preferredDefinition":"The name of the cell from which the biological specimen was derived._A symbol or combination of symbols which is assigned to the members of a collection.","longName":"12564956v1.00","context":"SWOG","contextVersion":"1","type":"Enumerated","dataType":"NUMBER","minLength":null,"maxLength":"2","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"1","valueDescription":null,"ValueMeaning":{"publicId":"3185303","version":"1","preferredName":"GCB","longName":"3185303v1.00","preferredDefinition":"A biologic subset of diffuse large B-cell lymphomas with a unique molecular signature or expression profile.  It represents approximately 50% of diffuse large B-cell lymphomas, and is characterized by the expression of CD10, BCL-6, A-myb, and LMO2 genes, BCL-2 translocation, and c-REL amplification.  Morphologically, the vast majority of these lymphomas are centroblastic and a small minority are immunoblastic (ratio20:1).  Patients with this type of diffuse large B-cell lymphoma have a more favorable outcome, with a 5-year survival rate of 60% and a median survival of 10 years.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type","conceptCode":"C36080","definition":"A biologic subset of diffuse large B-cell lymphomas with a unique molecular signature or expression profile.  It represents approximately 50% of diffuse large B-cell lymphomas, and is characterized by the expression of CD10, BCL-6, A-myb, and LMO2 genes, BCL-2 translocation, and c-REL amplification.  Morphologically, the vast majority of these lymphomas are centroblastic and a small minority are immunoblastic (ratio20:1).  Patients with this type of diffuse large B-cell lymphoma have a more favorable outcome, with a 5-year survival rate of 60% and a median survival of 10 years.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9A602691-7F26-B189-E040-BB89AD437FA7","latestVersionIndicator":"Yes","beginDate":"2011-01-21","endDate":null,"createdBy":"SHIDED","dateCreated":"2011-01-21","modifiedBy":"FINCHAMB","dateModified":"2023-02-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F4AC4638-B207-48EE-E053-731AD00AC0C9","beginDate":"2023-02-14","endDate":null,"createdBy":"FINCHAMB","dateCreated":"2023-02-14","modifiedBy":"FINCHAMB","dateModified":"2023-02-14","deletedIndicator":"No"},{"value":"2","valueDescription":null,"ValueMeaning":{"publicId":"3185301","version":"1","preferredName":"Non-GCB","longName":"3185301v1.00","preferredDefinition":"A biologic subset of diffuse large B-cell lymphomas with a unique molecular signature or expression profile.  It represents approximately 30% of diffuse large B-cell lymphomas, and is characterized by the expression of CD44, PKCbeta1, Cyclin D2, BCL-2, and IRF4/MUM1 genes.  Morphologically, these lymphomas are either centroblastic or immunoblastic (ratio 2:1).  Patients with this type of diffuse large B-cell lymphoma are reported to have a less favorable outcome compared to those with a germinal center B-cell expression profile, with a 5-year survival rate of 35% and a median survival of 2 years.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Diffuse Large B-Cell Lymphoma Activated B-Cell Type","conceptCode":"C36081","definition":"A biologic subset of diffuse large B-cell lymphomas with a unique molecular signature or expression profile.  It represents approximately 30% of diffuse large B-cell lymphomas, and is characterized by the expression of CD44, PKCbeta1, Cyclin D2, BCL-2, and IRF4/MUM1 genes.  Morphologically, these lymphomas are either centroblastic or immunoblastic (ratio 2:1).  Patients with this type of diffuse large B-cell lymphoma are reported to have a less favorable outcome compared to those with a germinal center B-cell expression profile, with a 5-year survival rate of 35% and a median survival of 2 years.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9A602691-7F00-B189-E040-BB89AD437FA7","latestVersionIndicator":"Yes","beginDate":"2011-01-21","endDate":null,"createdBy":"SHIDED","dateCreated":"2011-01-21","modifiedBy":"FINCHAMB","dateModified":"2023-02-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F4AC58A1-0876-4E30-E053-731AD00A63D9","beginDate":"2023-02-14","endDate":null,"createdBy":"FINCHAMB","dateCreated":"2023-02-14","modifiedBy":"FINCHAMB","dateModified":"2023-02-14","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"12564955","version":"1","preferredName":"Origin Cell Name Code","preferredDefinition":"The name of the cell from which the biological specimen was derived._A symbol or combination of symbols which is assigned to the members of a collection.","longName":"12564955v1.00","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Origin Cell Name","conceptCode":"C164570","definition":"The name of the cell from which the biological specimen was derived.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Code","conceptCode":"C25162","definition":"A symbol or combination of symbols which is assigned to the members of a collection.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F4AC3AF6-0B1F-471C-E053-731AD00A0822","latestVersionIndicator":"Yes","beginDate":"2023-02-14","endDate":null,"createdBy":"FINCHAMB","dateCreated":"2023-02-14","modifiedBy":"FINCHAMB","dateModified":"2023-02-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F4AC3AF6-0B20-471C-E053-731AD00A0822","latestVersionIndicator":"Yes","beginDate":"2023-02-14","endDate":null,"createdBy":"FINCHAMB","dateCreated":"2023-02-14","modifiedBy":"FINCHAMB","dateModified":"2023-11-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"PQT","type":"Preferred Question Text","description":"Cell of Origin","url":null,"context":"SWOG"}],"origin":"SWOG CRF:Southwest Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F4B0723B-303F-0BDC-E053-731AD00A4B3D","latestVersionIndicator":"Yes","beginDate":"2023-02-14","endDate":null,"createdBy":"FINCHAMB","dateCreated":"2023-02-14","modifiedBy":"FINCHAMB","dateModified":"2023-11-01","changeDescription":null,"administrativeNotes":"2/14/23 Created for SWOG S2207. BF;","unresolvedIssues":null,"deletedIndicator":"No"}}